BioMarin Q3 2026: First $1 Billion Quarter, Full-Year EPS Guidance Cut
As seen on the 24/7 Wall St. homepage on November 2, 2026.
BioMarin slashed full-year non-GAAP EPS guidance to $2.80-$3.10 from $4.90-$5.10 on Alesta and BMN 450 charges. Revenue crossed $1 billion for the first time on the Amicus deal, but a large international VOXZOGO order slipped into Q4.
Continue ReadingShow less
BioMarin's Q3 2026 non-GAAP EPS of $0.23 beat expectations, but full-year non-GAAP EPS guidance was cut to $2.80 to $3.10 from $4.90 to $5.10 on charges tied to the Alesta Therapeutics acquisition and the BMN 450 program.
The first fully consolidated quarter of the Amicus Therapeutics portfolio pushed total revenue past $1 billion for the first time, up 32% year over year.
Sponsored
Acquisition charges, amortization and interest on acquisition debt drove a GAAP net loss of $123 million, with total liabilities now at $5.3 billion.
Full-year 2026 revenue guidance was trimmed to $3.8 billion to $3.9 billion as an international VOXZOGO order slipped into Q4. CEO Alexander Hardy pointed to PDUFA dates of February 28, 2027 in achondroplasia and May 30, 2027 in hypochondroplasia as the next catalysts.
Sources
Mentioned: BMRN